HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review
DOI
- https://doi.org/10.1016/j.celrep.2020.108502
Final published version
- Rasmus Offersen, Ragon Institute of MGH, Massachusetts Institute of Technology ,
- Wen Han Yu, Massachusetts Institute of Technology ,
- Eileen P. Scully, Massachusetts Institute of Technology, Johns Hopkins University ,
- Boris Julg, Massachusetts Institute of Technology ,
- Zelda Euler, Massachusetts Institute of Technology ,
- Saheli Sadanand, Massachusetts Institute of Technology ,
- Dario Garcia-Dominguez, Massachusetts Institute of Technology ,
- Lu Zheng, Harvard University ,
- Thomas A. Rasmussen ,
- Madeleine F. Jennewein, Massachusetts Institute of Technology ,
- Caitlyn Linde, Massachusetts Institute of Technology ,
- Jessica Sassic, Massachusetts Institute of Technology ,
- Giuseppe Lofano, Massachusetts Institute of Technology ,
- Selena Vigano, Massachusetts Institute of Technology ,
- Kathryn E. Stephenson, Harvard University ,
- Stephanie Fischinger, Massachusetts Institute of Technology ,
- Todd J. Suscovich, Massachusetts Institute of Technology ,
- Mathias Lichterfeld, Harvard University ,
- Douglas Lauffenburger, Massachusetts Institute of Technology ,
- Erik S. Rosenberg, Harvard University ,
- Todd Allen, Massachusetts Institute of Technology ,
- Marcus Altfeld, Heinrich Pette Institute - Leibniz Institute for Experimental Virology ,
- Richelle C. Charles, Harvard University ,
- Lars Østergaard
- Martin Tolstrup
- Dan H. Barouch, Massachusetts Institute of Technology, Harvard University ,
- Ole S. Søgaard
- Galit Alter, Massachusetts Institute of Technology
Changes in antibody glycosylation are linked to inflammation across several diseases. Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections. However, whether changes in antibody Fc biology also track with reservoir rebound time remains unclear. The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies. Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts. Thus virus-specific antibody glycosylation may represent a promising, simply measured marker to track reservoir reactivation.
| Original language | English |
|---|---|
| Article number | 108502 |
| Journal | Cell Reports |
| Volume | 33 |
| Issue | 11 |
| Number of pages | 15 |
| ISSN | 2211-1247 |
| DOIs | |
| Publication status | Published - Dec 2020 |
- antibodies, B cells, biomarkers, cure, Fc-receptors, glycosylation, HIV, HIV remission, HIV reservoir, viral host response
Research areas
See relations at Aarhus University Citationformats
ID: 207031201